Italia markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
35,83+1,69 (+4,95%)
Alla chiusura: 04:00PM EST
35,74 -0,09 (-0,25%)
Dopo ore: 07:59PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente34,14
Aperto34,00
Denaro35,65 x 1100
Lettera35,74 x 1000
Min-Max giorno33,73 - 36,47
Intervallo di 52 settimane13,84 - 62,49
Volume1.164.203
Media Volume2.409.714
Capitalizzazione1,495B
Beta (5 anni mensile)0,08
Rapporto PE (ttm)N/D
EPS (ttm)-1,16
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendo13 dic 2012
Stima target 1A69,75
  • GlobeNewswire

    Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

    AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading

  • GlobeNewswire

    Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

    AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offer

  • GlobeNewswire

    Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

    – $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical program of simuf